Richard Vinisko

1.7k total citations
36 papers, 1.2k citations indexed

About

Richard Vinisko is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Richard Vinisko has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Richard Vinisko's work include Hepatitis C virus research (9 papers), HIV/AIDS drug development and treatment (9 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). Richard Vinisko is often cited by papers focused on Hepatitis C virus research (9 papers), HIV/AIDS drug development and treatment (9 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). Richard Vinisko collaborates with scholars based in United States, Germany and Spain. Richard Vinisko's co-authors include Philip M. Bath, Salim Yusuf, Otto W. Witte, Geoffrey A. Donnan, Bruce Ovbiagele, H.C. Diener, Renée H. Martin, Hans‐Christoph Diener, Akbar Panju and Bruce Ovbiagele and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Richard Vinisko

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Vinisko United States	15	368	307	230	212	204	36	1.2k
Michael Lin Australia	15	559 1.5×	214 0.7×	102 0.4×	175 0.8×	104 0.5×	54	1.4k
Petra Stohlawetz Austria	22	329 0.9×	167 0.5×	465 2.0×	205 1.0×	87 0.4×	37	1.7k
Hiroshi Osawa Japan	19	173 0.5×	210 0.7×	154 0.7×	124 0.6×	144 0.7×	120	1.2k
Cara East United States	21	107 0.3×	275 0.9×	477 2.1×	36 0.2×	245 1.2×	50	1.6k
Tracey E. Toms United Kingdom	23	134 0.4×	95 0.3×	381 1.7×	113 0.5×	151 0.7×	33	1.5k
Yuichi Kojima Japan	18	117 0.3×	322 1.0×	74 0.3×	84 0.4×	140 0.7×	102	1.1k
Maria Paola Garancini Italy	16	506 1.4×	174 0.6×	219 1.0×	172 0.8×	98 0.5×	24	1.6k
Timo Savunen Finland	21	334 0.9×	217 0.7×	374 1.6×	64 0.3×	38 0.2×	61	1.4k
Suefumi Aosasa Japan	20	298 0.8×	383 1.2×	58 0.3×	547 2.6×	106 0.5×	71	1.3k
Afroditi Katsaraki Greece	15	121 0.3×	86 0.3×	65 0.3×	133 0.6×	96 0.5×	32	943

Countries citing papers authored by Richard Vinisko

Since Specialization

Citations

This map shows the geographic impact of Richard Vinisko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Vinisko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Vinisko more than expected).

Fields of papers citing papers by Richard Vinisko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Vinisko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Vinisko. The network helps show where Richard Vinisko may publish in the future.

Co-authorship network of co-authors of Richard Vinisko

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Vinisko. A scholar is included among the top collaborators of Richard Vinisko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Vinisko. Richard Vinisko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hart, Simon P., Robert J. Kaner, Tejaswini Kulkarni, et al.. (2024). Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT. ERJ Open Research. 10(5). 310–2024.

Bentink, Stefan, Christian Heßlinger, Thomas B. Leonard, et al.. (2024). Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy. Lung. 202(5). 595–599. 1 indexed citations

Todd, Jamie L., Hongyu Zhao, Yi Liu, et al.. (2023). Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respiratory Research. 24(1). 141–141. 15 indexed citations

Wiebe, Sabrina, Alen Jambrecina, Armin Schultz, et al.. (2020). Midazolam microdosing applied in early clinical development for drug–drug interaction assessment. British Journal of Clinical Pharmacology. 87(1). 178–188. 10 indexed citations

Todd, Jamie L., Richard Vinisko, Yi Liu, et al.. (2020). Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine. 20(1). 64–64. 68 indexed citations

Visvanathan, Sudha, Ulf Müller‐Ladner, Meera Ramanujam, et al.. (2019). Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Annals of the Rheumatic Diseases. 78(6). 754–760. 44 indexed citations

Todd, Jamie L., Megan L. Neely, Robert Overton, et al.. (2019). Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research. 20(1). 227–227. 60 indexed citations

Visvanathan, Sudha, Patrick Baum, Richard Vinisko, et al.. (2018). Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. Journal of Allergy and Clinical Immunology. 143(6). 2158–2169. 58 indexed citations

Yong, Chan‐Loi, Joseph Gathe, Catherine Orrell, et al.. (2017). Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. HIV Clinical Trials. 18(5-6). 189–195. 3 indexed citations

10.

Zeuzem, Stefan, Parvez Mantry, Vincent Soriano, et al.. (2016). Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology & Hepatology. 28(8). 923–926. 1 indexed citations

11.

Sarrazin, Christoph, Francesco Castelli, Pietro Andreoné, et al.. (2016). HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clinical and Experimental Gastroenterology. Volume 9. 351–363. 2 indexed citations

12.

Berger, Kristi L., Christoph Sarrazin, David R. Nelson, et al.. (2016). Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. PLoS ONE. 11(8). e0160668–e0160668. 5 indexed citations

13.

Dieterich, Douglas T., Mark Nelson, Vincent Soriano, et al.. (2015). Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS. 29(5). 571–581. 10 indexed citations

14.

Zeuzem, Stefan, Jean‐François Dufour, Marı́a Buti, et al.. (2014). Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study. Liver International. 35(2). 417–421. 16 indexed citations

15.

NEUTEL, J, et al.. (2011). Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: teamsta severe HTN study. Canadian Journal of Diabetes. 35(2). 197–197. 4 indexed citations

16.

Ovbiagele, Bruce, H.C. Diener, Salim Yusuf, et al.. (2011). Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke. JAMA. 306(19). 2137–44. 160 indexed citations

17.

Huang, Fenglei, Paul Scholl, David B. Huang, et al.. (2010). Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(7). 1061–1070. 2 indexed citations

18.

Baxter, John D., et al.. (2010). Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study. Current HIV Research. 8(4). 347–354. 3 indexed citations

19.

Huang, Fenglei, Lynn C. Allen, David B. Huang, et al.. (2010). Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. Journal of Clinical Pharmacy and Therapeutics. 37(1). 81–88. 4 indexed citations

20.

Huang, Fenglei, Paul Scholl, David B. Huang, et al.. (2010). Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study. Basic & Clinical Pharmacology & Toxicology. 108(3). 163–170. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact